HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $43.
June 05, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BridgeBio Pharma and maintained a price target of $43.
The reiteration of a Buy rating and maintenance of a $43 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100